BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16007876)

  • 1. The radiotherapy reference panel--experiences and results of the German Hodgkin Study Group (GHSG).
    Eich HT; Müller RP
    Eur J Haematol Suppl; 2005 Jul; (66):98-105. PubMed ID: 16007876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
    Müller RP; Eich HT
    Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group.
    Eich HT; Engenhart-Cabillic R; Hansemann K; Lukas P; Schneeweiss A; Seegenschmiedt H; Skripnitchenko R; Staar S; Willich N; Müller RP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1419-24. PubMed ID: 18234433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).
    Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfart K; Lukas P; Plütschow A; Schmidberger H; Staar S; Fuchs M; Engert A; Eich HT
    Strahlenther Onkol; 2017 Feb; 193(2):109-115. PubMed ID: 27596217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
    Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group.
    Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfarth K; Lukas P; Schmidberger H; Marnitz-Schulze S; Fuchs M; Engert A; Eich HT
    Strahlenther Onkol; 2017 Feb; 193(2):100-108. PubMed ID: 27678010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of a teleradiotherapeutic network for patients in German lymphoma studies.
    Eich HT; Müller RP; Schneeweiss A; Hansemann K; Semrau R; Willich N; Rübe C; Sehlen S; Hinkelbein M; Diehl V
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):805-8. PubMed ID: 14967437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
    Eich HT; Gossmann A; Engert A; Kriz J; Bredenfeld H; Hansemann K; Skripnitchenko R; Brillant C; Pfistner B; Staar S; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1187-92. PubMed ID: 17703895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology].
    Eich HT; Müller RP; Ansén S; Josting A; Engert A; Hansemann K; Pfistner B; Wolf J; Willich N; Diehl V
    Rontgenpraxis; 2003; 55(3):114-24. PubMed ID: 15119314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control of involved-field radiotherapy for patients with early stage Hodgkin's lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group.
    Kriz J; Bangard C; Haverkamp U; Bongartz R; Baues C; Engert A; Mueller RP; Eich HT
    Strahlenther Onkol; 2012 Aug; 188(8):660-5. PubMed ID: 22692351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review.
    Bekelman JE; Yahalom J
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):492-8. PubMed ID: 18804334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A teleradiotherapeutic network for lymphoma patients within the competence network malignant lymphomas].
    Eich HT; Schneeweiss A; Skripnitchenko R; Hansemann K; Gossmann A; Müller RP
    Rontgenpraxis; 2007; 56(4):145-51. PubMed ID: 17390954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of radiation therapy within the German Hodgkin Study Group trials.
    Eich HT; Kriz J; Müller RP
    J Natl Compr Canc Netw; 2011 Sep; 9(9):1073-80. PubMed ID: 21917628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
    Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
    Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imaging.
    Eich HT; Staar S; Gossmann A; Engert A; Franklin J; Sieber M; Krug B; Diehl V; Lackner KJ; Müller RP;
    Am J Clin Oncol; 2004 Jun; 27(3):279-84. PubMed ID: 15170148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.
    Kriz J; Spickermann M; Lehrich P; Schmidberger H; Reinartz G; Eich H; Haverkamp U
    Strahlenther Onkol; 2015 Sep; 191(9):717-25. PubMed ID: 25876905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial.
    Oertel M; Hering D; Baues C; Kittel C; Fuchs M; Kriz J; Kröger K; Vordermark D; Herfarth K; Engenhart-Cabillic R; Lukas P; Haverkamp U; Borchmann P; Eich HT
    Front Oncol; 2023; 13():1183906. PubMed ID: 37213291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.
    Maraldo MV; Dabaja BS; Filippi AR; Illidge T; Tsang R; Ricardi U; Petersen PM; Schut DA; Garcia J; Headley J; Parent A; Guibord B; Ragona R; Specht L
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):144-52. PubMed ID: 25670544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.